Active, not recruitingNot applicableNCT03584022
Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial
Studying AA amyloidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Anthony J Windebank, MDMayo Clinic
- Intervention
- Biopsy + Nerve Repair(device)
- Enrollment
- 20 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2018 – 2027
Study locations (1)
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03584022 on ClinicalTrials.govOther trials for AA amyloidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06974877Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid LoadNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNCT06354322Unclassified GENotypes of Autoinflammatory Diseases and AA AmyloidosisAssistance Publique - Hôpitaux de Paris
- RECRUITINGNCT04265040DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research StudiesUniversity Hospital Heidelberg